tbuckley/cabot-search huggingface dataset:
Techniques and Thresholds for Quantifying Circulating Tumor Cells in Breast Cancer—In Reply
Authors: Joseph A. Sparano
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Real-Time Monitoring of Pharmacokinetics of Antibiotics in Biofilms with Raman-Tagged Hyperspectral Stimulated Raman Scattering Microscopy
Authors: Kideog Bae, Wei Zheng, Ying Ma, Zhiwei Huang
Journal: Theranostics (2019)

Antibiotics resistance developed by biofilms has posed a clinical challenge in the effective treatment of bacterial infections. However, the resistance mechanisms have not been well understood due to a lack of suitable tools for dynamic observation of the interplay between antibiotics and biofilm. In this work, with the use of rapid hyperspectral stimulated Raman scattering microscopy associated with an aryl-alkyne-based Raman tag synthesized, we investigate dynamic interactions between vancomycin and Staphylococcus aureus (
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Authors: Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM and mRCC patients. The efficacy and toxicity of HD IL-2 therapy following anti-PD-1 or anti-PD-L1 therapy have not yet been explored. <h3>Methods</h3> Reports on mM and mRCC patients who had received HD IL-2 after PD-1 or PD-L1 inhibition were queried from the PROCLAIM<sup>SM</sup> database. Patient characteristics, toxicity and efficacy were analyzed. <h3>Results</h3> A total of 57 patients (40 mM, 17 mRCC) were treated with high dose IL-2 after PD-1 or PD-L1 inhibition and had data recorded in the PROCLAIM database. The best overall response rate to HD IL-2 was 22.5% for mM (4 complete response (CR), 5 partial responses (PRs)) and 24% for mRCC (2 CRs, 2 PRs). The toxicity related to HD IL-2 observed in these patients was similar to that observed in patients treated with HD IL-2 without prior checkpoint blockade. One patient who had received prior PD-L1 blockade developed drug induced pneumonitis with HD IL-2 requiring steroid therapy. <h3>Conclusion</h3> In this retrospective analysis, HD IL-2 therapy displayed durable antitumor activity in mM and mRCC patients who progressed following treatment with PD-1 and PD-L1 inhibition. The toxicities were generally manageable and consistent with expectations from HD IL-2 but physicians should watch for immune related toxicities such as pneumonitis. This analysis supports the development of randomized prospective trials to assess the proper sequencing and combination of immune checkpoint blockade and cytokine therapy.
B cell–intrinsic requirement for STK4 in humoral immunity in mice and human subjects
Authors: Imogen Moran, Danielle T. Avery, Kathryn Payne, Helen Lenthall, E. Graham Davies, Siobhan Burns, Winnie Ip, Matÿfffedas M. Oleastro, Ismail Reisli, Sukru Guner, Sevgi Keles, Luigi Notarangelo, Elissa K. Deenick, Christopher C. Goodnow, David Zahra, Robert Brink, Melanie Wong, Stuart G. Tangye, Cindy S. Ma, Tri Giang Phan
Journal: Journal of Allergy and Clinical Immunology (2019)
Zinc Supplementation Improves T Cell Reconstitution after Allogeneic HSCT By Stimulating Endogenous Pathways of Thymic Regeneration
Authors: Lorenzo Iovino, Kirsten Cooper, Sinéad Kinsella, Paul DeRoos, Reema Jain, Sara Galimberti, Enrico Orciuolo, Edoardo Benedetti, Mario Petrini, Jarrod A Dudakov
Journal: Blood (2018)
Whipped Cream—Viennese Ballet and Pop Surrealism Meet Dark Medicine
Authors: Jason F. Wang, Nicholas A. Soter, Simon A. Morrison
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer
Authors: Miguel Reina-Campos, Juan F. Linares, Angeles Duran, Thekla Cordes, Antoine L'Hermitte, Mehmet G. Badur, Munveer S. Bhangoo, Phataraporn K. Thorson, Alicia Richards, Tarmo Rooslid, Dolores C. Garcia-Olmo, Syongh Y. Nam-Cha, Antonio S. Salinas-Sanchez, Ken Eng, Himisha Beltran, David A. Scott, Christian M. Metallo, Jorge Moscat, Maria T. Diaz-Meco
Journal: Cancer Cell (2019)
Abstract 4821: Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
Authors: Jill Spoerke, Carol O'Brien, Jenny Wu, Rupal Desai, Rajesh Patel, Rajiv Raja, Hartmut Koeppen, Lukas Amler, Garret Hampton, Yibing Yan, Mark R. Lackner
Journal: Cancer Research (2012)

Abstract Background: The PI3K/Akt pathway is frequently activated in cancer by multiple mechanisms including PI3K activating mutations, PTEN loss, RTK activation, and other means. GDC-0941 and GDC-0980 are selective PI3K and dual PI3K/mTOR inhibitors, respectively, which are currently in phase II clinical development. Assays for candidate predictive and pharmacodynamic biomarkers were conducted on patient samples collected from phase I studies of GDC-0941 and GDC-0980. The purpose was to confirm pathway inhibition at tolerable doses, as well as look for association between anti-tumor activity and candidate predictive biomarkers. Methods: Archival tumor tissue samples were analyzed using a 6 gene mutation assay (PIK3CA, EGFR, KRAS, BRAF, NRAS, AKT1), an immunohistochemistry assay for PTEN, and a fluorescence in situ hybridization (FISH) assay for PIK3CA. Select samples were analyzed for an expanded mutation panel and genome-wide copy number alterations using the Oncoscan platform (Affymetrix). For pharmacodynamic biomarker assays, analyses were initially limited to pre and post treatment phospho-AKT levels in platelet rich plasma. Once substantial downmodulation of pAKT in surrogate tissue was observed, pre- and post treatment biopsies were collected from a subset of patients and analyzed for phospho-S6 levels by immunohistochemistry. Results: Predictive biomarker assays were conducted on over 150 samples from the phase I study. Overall we found a prevalence of 7% PIK3CA mutations and 15% loss of PTEN in these samples. PIK3CA amplification was observed in several samples from ovarian cancer patients. Overall there were five confirmed partial responses in the studies, and two of these occurred in patients with activating mutations in PIK3CA. Robust PD knockdown of pAKT in surrogate tissue was observed in the early stage of dose-escalation. Moreover, substantial knockdown of pS6 was seen in tumor tissues in patients treated at or below the recommended phase II dose. Conclusions: Pharmacodynamic assays confirmed effective pathway knockdown at safe and tolerated clinical doses of GDC-0941 and GDC-0980. Anti-tumor activity was observed in patients with PIK3CA mutations, as well as some patients whose tumors did not harbor pathway alterations. These data support patient stratification in phase II clinical studies to determine whether a predictive biomarker will be useful in identifying responsive patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4821. doi:1538-7445.AM2012-4821
Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia
Authors: Neus Giménez Carabaza, Rosich Laia, Schulz Ralph, Higashi Morihiro, Marta Aymerich, Neus Villamor, Julio Delgado, Manel Juan, Monica Lopez-Guerra, Elias Campo, Martina Seiffert, Dolors Colomer
Journal: Blood (2018)
Persistent Antibody Clonotypes Dominate the Serum Response to Influenza over Multiple Years and Repeated Vaccinations
Authors: Jiwon Lee, Philipp Paparoditis, Andrew P. Horton, Alexander Frühwirth, Jonathan R. McDaniel, Jiwon Jung, Daniel R. Boutz, Dania A. Hussein, Yuri Tanno, Leontios Pappas, Gregory C. Ippolito, Davide Corti, Antonio Lanzavecchia, George Georgiou
Journal: Cell Host & Microbe (2019)
The Highly Prevalent Deletions in F8 Intron 13 Found in French Mild Haemophilia a Patients Result of Both Founder Effect and Recurrent De Novo Events
Authors: Yohann Jourdy, Mathilde Fretigny, Fanny Lassalle, David Lillicrap, Claude Negrier, Patrice Bouvagnet, Christine Vinciguerra
Journal: Blood (2018)
Trends in Tuberculosis—United States, 2005
Journal: JAMA (2006)

reducing contamination and illness related to ground beef. 8,9onsumers can reduce their risk for foodborne illness by following safe food-handling recommendations and by avoiding consumption of unpasteurized milk and unpasteurized milk products, raw or undercooked oysters, raw or undercooked eggs, raw or undercooked ground beef, and undercooked poultry (additional information on food safety for consumers is available at http://www .fightbac.org).Other effective prevention measures, such as pasteurization of in-shell eggs, irradiation of ground meat, and pressure treatment of oysters, can also decrease the risk for foodborne illness.
Post-Transplant Cyclophosphamide and Sirolimus in Matched Related and Unrelated Allogeneic Transplant with a Treosulfan-Based Conditioning
Authors: Jacopo Peccatori, Serena Albanese, Raffaella Greco, Francesca Lorentino, Fabio Giglio, Daniela Clerici, Lorenzo Lazzari, Maria Teresa Lupo Stanghellini, Simona Piemontese, Magda Marcatti, Sara Mastaglio, Andrea Assanelli, Luca Vago, Consuelo Corti, Massimo Bernardi, Fabio Ciceri
Journal: Blood (2018)
Erythropoietin reduces collagen deposition after myocardial infarction butdoes not improve cardiac function in male rats
Authors: F. Fernanda Pessoa, C. Mady, K. C. B. Fonseca, O. N. Ribeiro, V. M. C. Salemi, M. R. Jordao, F. Fernandes, F. J. A. Ramires
Journal: European Journal of Heart Failure (2017)
Influence of short-term changes in dietary sulfur on the relative abundances of intestinal sulfate-reducing bacteria
Authors: Allison Dostal Webster, Christopher Staley, Matthew J. Hamilton, Merry Huang, Kathryn Fryxell, Raymond Erickson, Amanda J. Kabage, Michael J. Sadowsky, Alexander Khoruts
Journal: Gut Microbes (2019)

High-protein diets may be linked to gut inflammation due to increased production of hydrogen sulfide (H2S), a potential toxin, as an end product of microbial fermentation in the colon by sulfidogenic sulfate-reducing bacteria (SRB). We hypothesized that dietary content of sulfur-containing amino acids (SAA) leads to variation in the relative abundances of intestinal SRB, which include Desulfovibrio and Bilophila taxa. To test this hypothesis we performed a pilot crossover study in four healthy volunteers, who consumed two interventional diets for 10–14 days, containing high or low SAA content. The total energy intake was similar between the two dietary extremes. Microbial communities were characterized by 16S rRNA gene amplicon and shotgun next-generation DNA sequencing. While the relative abundance of Desulfovibrio differed among participants (ANOVA P= 0.001), we could not detect a change with dietary treatments. Similarly, no differences in Bilophila abundance were observed among individuals or dietary arms. Inter-personal differences in microbial community composition and functional gene categories differed between subjects and these differences were maintained over the course of the study. These observations are consistent with re-analysis of two previously published dietary intervention studies. Finally, we found that inter-personal differences in the taxonomic composition of fecal microbiota, including the relative abundances of SRB, were maintained over time in 19 healthy individuals in our stool donor program. These results suggest that the use of dietary interventions alone may be insufficient for rapid therapeutic targeting of SRB. Nevertheless, these pilot data provide a foundation to inform future, statistically powered, studies.
Abstract P3-13-02: Withdrawn
Authors: PH Cottu, V D'Hondt, S Dureau, F Lerebours, I Desmoulins, P Heudel, F Duhouix, C Levy, M-A Mouret-Reynier, F Dalenc, J-S Frenel, C Jouannaud, L Venat-Bouvet, S Nguyen, J-M Ferrero, J-L Canon, J Grenier, A Vincent-Salomon, J Lemonnier, S Delaloge
Journal: Cancer Research (2018)

Abstract This abstract was withdrawn by the authors.
Update in Diffuse Parenchymal Lung Disease 2006
Authors: Athol U Wells, Cory M Hogaboam
Journal: American Journal of Respiratory and Critical Care Medicine (2007)

IIPs Prevalence of disease. Epidemiology is necessarily an inexact science. Previous statements of the incidence and prevalence of IPF have largely centered on death certification and disease registries (1, 2). Clinical diagnostic criteria, which are sensitive but not specific for IPF, capture other disorders with the clinical features of IPF, including NSIP, other IIPs, and patients with undiagnosed hypersensitivity pneumonitis (HP). Imprecision in the estimation of the prevalence of IPF is well illustrated in a recent evaluation of a U.S. health care claims database (3). Based on narrow case definitions, requiring the performance of a biopsy procedure (surgical or transbronchial biopsy) or high-resolution computed tomography (HRCT), the incidence and prevalence of IPF in the United States were estimated to be 6.8 per 100,000 and 14 per 100,000, respectively. However, with more liberal diagnostic criteria, these figures rose strikingly to 16.3 per 100,000 and 42.7 per 100,000, respectively. As the true figure lies somewhere between these estimates, IPF appears to be substantially more prevalent than previously reported, a conclusion supported by a reported incidence of 6.8 per 100,000 in the United Kingdom, in 2000–2003 (4). It is not clear whether these findings primarily represent changes in clinician diagnostic thresholds or whether there has been a real increase in disease prevalence. However, this uncertainty should not obscure the fact that IPF appears to be approximately as prevalent as a number of the more common malignancies, all of which attract a much larger share of community and research resources. Acute exacerbations of IPF have historically been viewed as rare events, a perception challenged by a surprisingly high prevalence of rapid deterioration in the inactive arms of three intervention studies (5–7). A 2-year frequency of acute exacerbations of approximately 10% has now been reported in a cohort of 147 patients with IPF (8), underlining the need for a reappraisal of the risk factors and management of this often-lethal disorder.
Progress Toward Regional Measles Elimination — Worldwide, 2000–2014
Authors: Robert T. Perry, Jillian S. Murray, Marta Gacic-Dobo, Alya Dabbagh, Mick N. Mulders, Peter M. Strebel, Jean-Marie Okwo-Bele, Paul A. Rota, James L. Goodson
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

In 2000, the United Nations General Assembly adopted the Millennium Development Goals (MDG), with MDG4 being a two-thirds reduction in child mortality by 2015, and with measles vaccination coverage being one of the three indicators of progress toward this goal.* In 2010, the World Health Assembly established three milestones for measles control by 2015: 1) increase routine coverage with the first dose of measles-containing vaccine (MCV1) for children aged 1 year to ≥90% nationally and ≥80% in every district; 2) reduce global annual measles incidence to fewer than five cases per million population; and 3) reduce global measles mortality by 95% from the 2000 estimate (1).† In 2012, the World Health Assembly endorsed the Global Vaccine Action Plan§ with the objective to eliminate measles in four World Health Organization (WHO) regions by 2015. WHO member states in all six WHO regions have adopted measles elimination goals. This report updates the 2000–2013 report (2) and describes progress toward global control and regional measles elimination during 2000–2014. During this period, annual reported measles incidence declined 73% worldwide, from 146 to 40 cases per million population, and annual estimated measles deaths declined 79%, from 546,800 to 114,900. However, progress toward the 2015 milestones and elimination goals has slowed markedly since 2010. To resume progress toward milestones and goals for measles elimination, a review of current strategies and challenges to improving program performance is needed, and countries and their partners need to raise the visibility of measles elimination, address barriers to measles vaccination, and make substantial and sustained additional investments in strengthening health systems.
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Authors: Grant M. Fischer, Ali Jalali, David A. Kircher, Won-Chul Lee, Jennifer L. McQuade, Lauren E. Haydu, Aron Y. Joon, Alexandre Reuben, Mariana P. de Macedo, Fernando C. L. Carapeto, Chendong Yang, Anuj Srivastava, Chandrashekar R. Ambati, Arun Sreekumar, Courtney W. Hudgens, Barbara Knighton, Wanleng Deng, Sherise D. Ferguson, Hussein A. Tawbi, Isabella C. Glitza, Jeffrey E. Gershenwald, Y. N. Vashisht Gopal, Patrick Hwu, Jason T. Huse, Jennifer A. Wargo, P. Andrew Futreal, Nagireddy Putluri, Alexander J. Lazar, Ralph J. DeBerardinis, Joseph R. Marszalek, Jianjun Zhang, Sheri L. Holmen, Michael T. Tetzlaff, Michael A. Davies
Journal: Cancer Discovery (2019)

Abstract There is a critical need to improve our understanding of the pathogenesis of melanoma brain metastases (MBM). Thus, we performed RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial metastases; tumors with sufficient tissue also underwent whole-exome sequencing, T-cell receptor sequencing, and IHC. MBMs demonstrated heterogeneity of immune infiltrates that correlated with prior radiation and post-craniotomy survival. Comparison with patient-matched extracranial metastases identified significant immunosuppression and enrichment of oxidative phosphorylation (OXPHOS) in MBMs. Gene-expression analysis of intracranial and subcutaneous xenografts, and a spontaneous MBM model, confirmed increased OXPHOS gene expression in MBMs, which was also detected by direct metabolite profiling and [U-13C]-glucose tracing in vivo. IACS-010759, an OXPHOS inhibitor currently in early-phase clinical trials, improved survival of mice bearing MAPK inhibitor–resistant intracranial melanoma xenografts and inhibited MBM formation in the spontaneous MBM model. The results provide new insights into the pathogenesis and therapeutic resistance of MBMs. Significance: Improving our understanding of the pathogenesis of MBMs will facilitate the rational development and prioritization of new therapeutic strategies. This study reports the most comprehensive molecular profiling of patient-matched MBMs and extracranial metastases to date. The data provide new insights into MBM biology and therapeutic resistance. See related commentary by Egelston and Margolin, p. 581. This article is highlighted in the In This Issue feature, p. 565
Abstract 11933: Determining the Risks of Magnetic Resonance Imaging at 1.5 Tesla for Patients With Pacemakers and Implantable Cardioverter Defibrillators (the MagnaSafe Registry)
Authors: Robert Russo, Heather Costa, Ashish Kabra, Seth Uretsky, Steven D Wolff, Edward T Martin, Steven Higgins, Gail Tominaga, Christian Machado, Todd Florin, Daniel C Bloomgarden, Ulrika Birgersdotter-Green, George Ponce, Raymond Schaerf, Rachel Lampert, Dipan Shah, Aysha Arshad, Allison Tonkin, Jeffrey Anderson, Andrew Rivard, Douglas A Wolfe, Robert Biederman, Jason Rubenstein, Gery Tomassoni, Noel G Boyle
Journal: Circulation (2013)

Objective: The MagnaSafe Registry is a multicenter study designed to determine the risk of MRI at 1.5T in 1500 patients with pacemakers (PM) and implantable cardioverter-defibrillators (ICD) who un...
Authors’ reply to Zedan and De Ru and Bayoumy
Authors: Jonathan M Fishman, Laura M Cullen
Journal: BMJ (2019)

We agree with Zedan that sudden sensorineural hearing loss is an ear, nose, and throat emergency, and we emphasised this in our article.12 Such patients should be dealt with promptly with the aim of preserving cochlear function. Additional treatments are warranted for this devastating condition. New drugs are currently …
West Nile Virus and Other Nationally Notifiable Arboviral Diseases — United States, 2014
Authors: Nicole P. Lindsey, Jennifer A. Lehman, J. Erin Staples, Marc Fischer
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

Arthropod-borne viruses (arboviruses) are transmitted to humans primarily through the bites of infected mosquitoes and ticks. West Nile virus (WNV) is the leading cause of domestically acquired arboviral disease in the United States (1). However, several other arboviruses also cause sporadic cases and seasonal outbreaks. This report summarizes surveillance data reported to CDC in 2014 for WNV and other nationally notifiable arboviruses, excluding dengue. Forty-two states and the District of Columbia (DC) reported 2,205 cases of WNV disease. Of these, 1,347 (61%) were classified as WNV neuroinvasive disease (e.g., meningitis, encephalitis, or acute flaccid paralysis), for a national incidence of 0.42 cases per 100,000 population. After WNV, the next most commonly reported cause of arboviral disease was La Crosse virus (80 cases), followed by Jamestown Canyon virus (11), St. Louis encephalitis virus (10), Powassan virus (8), and Eastern equine encephalitis virus (8). WNV and other arboviruses cause serious illness in substantial numbers of persons each year. Maintaining surveillance programs is important to help direct prevention activities.